Published in Proc Natl Acad Sci U S A on December 23, 2013
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Genomic and global approaches to unravelling how hypermutable sequences influence bacterial pathogenesis. Pathogens (2014) 0.82
Differential expression of small RNAs from Burkholderia thailandensis in response to varying environmental and stress conditions. BMC Genomics (2014) 0.81
In-silico prediction and deep-DNA sequencing validation indicate phase variation in 115 Neisseria meningitidis genes. BMC Genomics (2016) 0.76
Evolution of Bacterial Pathogens Within the Human Host. Microbiol Spectr (2016) 0.75
Lactoferrin binding protein B - a bi-functional bacterial receptor protein. PLoS Pathog (2017) 0.75
Interstrain Cooperation in Meningococcal Biofilms: Role of Autotransporters NalP and AutA. Front Microbiol (2017) 0.75
Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells. PLoS One (2016) 0.75
The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection. PLoS One (2016) 0.75
Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase. PLoS Pathog (2017) 0.75
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet (2007) 5.11
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
The covalent-binding reaction of complement component C3. Biochem J (1981) 2.80
Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol Microbiol (2000) 2.44
Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A (1985) 2.38
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun (2008) 2.29
Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nat Rev Microbiol (2009) 1.87
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis (2009) 1.67
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol (2003) 1.56
Bacterial complement evasion. Mol Immunol (2006) 1.54
Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol (2010) 1.52
Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog (2011) 1.42
Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun (2008) 1.39
C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med (1995) 1.36
Autotransported serine protease A of Neisseria meningitidis: an immunogenic, surface-exposed outer membrane, and secreted protein. Infect Immun (2002) 1.36
Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem (2007) 1.29
Polar localization of the autotransporter family of large bacterial virulence proteins. J Bacteriol (2006) 1.24
Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J Immunol (2011) 1.20
The interaction of primate transferrins with receptors on bacteria pathogenic to humans. Microb Pathog (1993) 1.15
Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev (2011) 1.15
Immune evasion of Enterococcus faecalis by an extracellular gelatinase that cleaves C3 and iC3b. J Immunol (2008) 1.12
C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol (1994) 1.06
C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood (1994) 1.05
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol (2012) 1.04
EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5. Infect Immun (2010) 1.02
NalP-mediated proteolytic release of lactoferrin-binding protein B from the meningococcal cell surface. Infect Immun (2010) 1.00
The surface protease PgtE of Salmonella enterica affects complement activity by proteolytically cleaving C3b, C4b and C5. FEBS Lett (2007) 0.99
A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis. Microbes Infect (2006) 0.97
Involvement of three meningococcal surface-exposed proteins, the heparin-binding protein NhbA, the α-peptide of IgA protease and the autotransporter protease NalP, in initiation of biofilm formation. Mol Microbiol (2012) 0.96
Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res Mol Brain Res (2003) 0.94
Complement: an efficient sword of innate immunity. Contrib Microbiol (2008) 0.88
Prevalence and phase variable expression status of two autotransporters, NalP and MspA, in carriage and disease isolates of Neisseria meningitidis. PLoS One (2013) 0.84
Lipidation of the autotransporter NalP of Neisseria meningitidis is required for its function in the release of cell-surface-exposed proteins. Microbiology (2012) 0.82
Expression of the third complement component (C3) and carboxypeptidase N small subunit (CPN1) during mouse embryonic development. Dev Comp Immunol (2004) 0.81
Bacterial complement escape. Adv Exp Med Biol (2009) 0.81
Purified meningococcal transferrin-binding protein B interacts with a secondary, strain-specific, binding site in the N-terminal lobe of human transferrin. Biochem J (1999) 0.78
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
The microbial pan-genome. Curr Opin Genet Dev (2005) 5.93
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Microbiology in the post-genomic era. Nat Rev Microbiol (2008) 4.88
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol (2002) 3.20
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Genomic characterization of non-O1, non-O139 Vibrio cholerae reveals genes for a type III secretion system. Proc Natl Acad Sci U S A (2005) 2.65
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome Biol (2010) 2.60
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun (2008) 2.29
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Mol Microbiol (2004) 2.08
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Influenza vaccine immunology. Immunol Rev (2011) 2.02
A type III secretion system in Vibrio cholerae translocates a formin/spire hybrid-like actin nucleator to promote intestinal colonization. Cell Host Microbe (2007) 2.02
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Vaccine manufacturing: challenges and solutions. Nat Biotechnol (2006) 1.73
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
Interactions between Neisseria meningitidis and the complement system. Trends Microbiol (2007) 1.72
A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol (2008) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol (2011) 1.68
Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 1.68
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A (2007) 1.64
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
Phylogeny of the SARS coronavirus. Science (2003) 1.56
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis (2004) 1.55
Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol (2010) 1.52
Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis (2008) 1.49
Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47
Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol (2012) 1.47
Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A. PLoS Pathog (2008) 1.45
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog (2011) 1.42
NadA diversity and carriage in Neisseria meningitidis. Infect Immun (2004) 1.40
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines (2013) 1.39
Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol (2008) 1.39
Italy must invest more in science and technology. Nature (2008) 1.38
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
In vitro analysis of protein-operator interactions of the NikR and fur metal-responsive regulators of coregulated genes in Helicobacter pylori. J Bacteriol (2005) 1.36
The Lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappaB activation in epithelial cells in a Toll-like receptor 2-dependent manner. J Biol Chem (2003) 1.35
Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med (2009) 1.32
Autoregulation of Helicobacter pylori Fur revealed by functional analysis of the iron-binding site. Mol Microbiol (2002) 1.32
Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Infect Immun (2008) 1.32
Vaccinology in the genome era. J Clin Invest (2009) 1.31
Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine (2010) 1.30
Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. Mol Microbiol (2006) 1.30
The role of porins in neisserial pathogenesis and immunity. Trends Microbiol (2003) 1.30
Growth phase-dependent regulation of target gene promoters for binding of the essential orphan response regulator HP1043 of Helicobacter pylori. J Bacteriol (2002) 1.29
Molecular architecture of Streptococcus pneumoniae TIGR4 pili. EMBO J (2009) 1.29
Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A (2011) 1.27
Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure. Proc Natl Acad Sci U S A (2014) 1.27
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis (2004) 1.27
Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol (2008) 1.27
Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology (2008) 1.26